SEC Filings

KERYX BIOPHARMACEUTICALS INC filed this Form 424B5 on 07/27/2017
Entire Document

Table of Contents


The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not contain all the information that may be important to you. For a more complete understanding of our common stock, you should read this prospectus supplement and the accompanying prospectus and the documents referred to herein and therein.



Keryx Biopharmaceuticals, Inc.


Common stock offered by us

Shares of our common stock having an aggregate offering price of up to $75,000,000.


Common stock to be outstanding after this offering

Up to 128,598,520 shares (as more fully described in the notes following this table), assuming sales of 10,094,212 shares of our common stock in this offering at an assumed offering price of $7.43 per share, which was the last reported sale price of our common stock on the NASDAQ Capital Market on July 26, 2017. The actual number of shares issued in connection with this offering will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur.


Plan of Distribution

Sales of shares of our common stock under this prospectus supplement and the accompanying prospectus may be made by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Subject to the terms of the sales agreement, Cantor Fitzgerald & Co. will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The NASDAQ Capital Market, on mutually agreeable terms between Cantor Fitzgerald & Co. and us. See “Plan of Distribution” beginning on page S-12 of this prospectus supplement.


Sales agent

Cantor Fitzgerald & Co.


Use of Proceeds

We expect to use the net proceeds from this offering, if any, for working capital and general corporate purposes. See “Use of Proceeds” beginning on page S-9 of this prospectus supplement.


Risk Factors

Your investment in shares of our common stock involves substantial risks. You should consider the matters referred to under the heading “Risk Factors” in this prospectus supplement and the accompanying prospectus, including the risk factors incorporated by reference herein and therein from our filings with the SEC.


NASDAQ Capital Market symbol


The number of shares of common stock shown above to be outstanding after this offering is based on 118,504,308 shares of our common stock outstanding as of June 30, 2017, including 2,156,643 shares of unvested restricted stock subject to repurchase by us, and excluding:


    12,468,869 shares of our common stock reserved for issuance upon the exercise of outstanding stock options at a weighted average exercise price of $6.64 per share;